Core Points - Sharp Therapeutics Corp. is arranging a non-brokered private placement to raise at least US$10,000,000, with shares priced at a minimum of US$2.50 each, expected to close in Q4 2025 [1] - STX Partners, Sharp's largest shareholder, has committed to purchase at least 1,200,000 shares for approximately US$3,000,000, contingent on the company raising at least US$7,000,000 from other investors [2] - The insider participation in the offering is classified as a related-party transaction, exempt from formal evaluation or minority shareholder approval under Multilateral Instrument 61-101 [3] Company Insights - Sharp Therapeutics is a preclinical-stage company focused on developing small-molecule therapeutics for genetic diseases, utilizing high throughput screening technologies and computationally optimized compound libraries [6] - The company aims to produce small molecule compounds that restore activity in mutated proteins, potentially allowing for treatment of genetic disorders with conventional pill-based medicines [6] Management Statements - John Hathaway, managing partner of STX, expressed excitement about continuing investment in Sharp and highlighted the scientific progress, particularly regarding the Gaucher development candidate [4] - Scott Sneddon, CEO of Sharp, noted the significance of STX's commitment in supporting the company's Phase I trials for its candidate '901, an oral treatment for Gaucher disease and other lysosomal storage disorders [4]